Daniel A Pomeranz Krummel, Tahseen H Nasti, Milota Kaluzova, Laura Kallay, Debanjan Bhattacharya, Johannes C Melms, Benjamin Izar, Maxwell Xu, Andre Burnham, Taukir Ahmed, Guanguan Li, David Lawson, Jeanne Kowalski, Yichun Cao, Jeffrey M Switchenko, Dan Ionascu, James M Cook, Mario Medvedovic, Andrew Jenkins, Mohammad K Khan, Soma Sengupta
PURPOSE: Most patients with metastatic melanoma show variable responses to radiation therapy and do not benefit from immune checkpoint inhibitors. Improved strategies for combination therapy that leverage potential benefits from radiation therapy and immune checkpoint inhibitors are critical. METHODS AND MATERIALS: We analyzed metastatic melanoma tumors in the TCGA cohort for expression of genes coding for subunits of type A γ-aminobutyric acid (GABA) receptor (GABAA R), a chloride ion channel and major inhibitory neurotransmitter receptor...
October 24, 2020: International Journal of Radiation Oncology, Biology, Physics